Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 44 Lung Neoplasms 9 Brain Neoplasms 7 NSCLC 3 Pancreatic Neoplasms 2 Neoplasms 2 Nasopharyngeal Carcinoma 2 Esophageal Neoplasms 2 EGF-R Positive Non-Small Cell Lung Cancer 2 Adenocarcinoma of Lung 2 Adenocarcinoma 2 Squamous Cell Carcinoma of Lung 1 Plasma EGFR Mutation-positive Lung Cancer 1 Non-squamous Non-small Cell Lung Cancer 1 Non-small Cell Lung Cancer Metastatic 1 Non-Small-Cell Lung 1 Neuroma, Acoustic 1 Neurofibromatosis 2 1 Neoplasms, Second Primary 1 Neoplasm Metastasis 1 Drug-Related Side Effects and Adverse Reactions 1 Bronchial Neoplasms 1 Breast Neoplasms 1

Interventions

Bevacizumab 5 Everolimus 4 Sirolimus 2 Lapatinib 2 HDAC-42 2 vistusertib 1 temsirolimus 1 neratinib 1 icotinib 1 emvododstat 1 brolucizumab 1 brigatinib 1 aflibercept 1 Vascular Endothelial Growth Factor A 1 Valproic Acid 1 Sunitinib 1 Magnetic Resonance Imaging 1 Immunoglobulin G 1 Endostatins 1 Doxycycline 1 Disulfides 1 Crizotinib 1 Cetuximab 1 Axitinib 1 Aspirin 1 AZD 6244 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neurofibromatosis 2 × icotinib × Clear all

NCT02934256 2021-09-09

Icotinib

Beijing Tiantan Hospital

Phase 2 Completed

Neuroma, Acoustic, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡